AbbVie (NYSE: ABBV) is one of the newer pharmaceutical companies to take the market by storm. The stock has still about 5% off its all-time highs from 2018, and if AbbVie's recent first-quarter earnings tell us anything, it's that the stock can go even higher. AbbVie reported its first-quarter earnings last week, and beat analyst estimates on most metrics.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting